Early treatment failure during treatment of <it>Plasmodium falciparum</it> malaria with atovaquone-proguanil in the Republic of Ivory Coast

Early treatment failure during treatment of <it>Plasmodium falciparum</it> malaria with atovaquone-proguanil in the Republic of Ivory Coast

<p>Abstract</p> <p>The increased spread of drug-resistant malaria highlights the need for alternative drugs for treatment and chemoprophylaxis. The combination of atovaquone‐proguanil (Malarone®) has shown high efficacy against <it>Plasmodium falciparum</it> with only m...

Full description

Bibliographic Details
Main Authors:	Wurtz Nathalie, Pascual Aurélie, Marin-Jauffre Adeline, Bouchiba Housem, Benoit Nicolas, Desbordes Marc, Martelloni Maryse, de Santi Vincent, Richa Georges, Taudon Nicolas, Pradines Bruno, Briolant Sébastien
Format:	Article
Language:	English
Published:	BMC 2012-05-01
Series:	Malaria Journal
Subjects:	Malaria Plasmodium falciparum Malarone® Atovaquone-proguanil Cytochrome b Resistance Clinical failure in vitro Anti-malarial drug
Online Access:	http://www.malariajournal.com/content/11/1/146

Similar Items

Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru
by: A. Llanos-Cuentas, et al.

Atovaquone and proguanil hydrochloride compared with chloroquine or pyrimethamine/sulfadoxine for treatment of acute Plasmodium falciparum malaria in Peru
by: Llanos-Cuentas A., et al.
Published: (2001-01-01)

A survey on outcomes of accidental atovaquone–proguanil exposure in pregnancy
by: Kathrine R. Tan, et al.
Published: (2018-05-01)

Proguanil and atovaquone use is associated with lower colorectal cancer risk: a nationwide cohort study
by: Naiqi Zhang, et al.
Published: (2022-11-01)

A Safe and Effective Atovaquone-Proguanil Therapeutic Protocol for the Treatment of Avian Malaria by <i>Plasmodium relictum</i> in Snowy Owl (<i>Bubo scandiacus</i>)
by: Nicola Pugliese, et al.
Published: (2023-11-01)

Superior protection in a relapsing Plasmodium cynomolgi rhesus macaque model by a chemoprophylaxis with sporozoite immunization regimen with atovaquone-proguanil followed by primaquine
by: Kosol Yongvanitchit, et al.
Published: (2024-04-01)

Tolerability of Atovaquone—Proguanil Application in Common Buzzard Nestlings
by: Anja Wiegmann, et al.
Published: (2022-07-01)

Clinical Efficacy and Safety of Malarone<sup>®</sup>, Azithromycin and Artesunate Combination for Treatment of <i>Babesia gibsoni</i> in Naturally Infected Dogs
by: Martina Karasová, et al.
Published: (2022-03-01)

"Pyrimethamine and Proguanil Resistance-Conferring Key Mutations in Dihydrofolate Reductase Gene of Plasmodium falciparum Isolates from Iran"
by: AA Eskandarian, et al.
Published: (2003-12-01)

"Pyrimethamine and Proguanil Resistance-Conferring Key Mutations in Dihydrofolate Reductase Gene of Plasmodium falciparum Isolates from Iran"
by: AA Eskandarian, et al.
Published: (2003-10-01)

Babesiosis in Long Island: review of 62 cases focusing on treatment with azithromycin and atovaquone
by: Ekaterina A. Kletsova, et al.
Published: (2017-04-01)

Efficacy of atovaquone and sulfadiazine in the treatment of mice infected with Toxoplasma gondii strains isolated in Brazil
by: Alves C.F., et al.
Published: (2005-06-01)

Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates
by: Maarten van der Velden, et al.
Published: (2017-10-01)

Atovaquone and Berberine Chloride Reduce SARS-CoV-2 Replication In Vitro
by: Bruno A. Rodriguez-Rodriguez, et al.
Published: (2021-12-01)

Toxoplasmosis Complications and Novel Therapeutic Synergism Combination of Diclazuril plus Atovaquone
by: Helieh S Oz
Published: (2014-09-01)

Atovaquone attenuates experimental colitis by reducing neutrophil infiltration of colonic mucosa
by: Laura D. Manzanares, et al.
Published: (2022-10-01)

Reversible Cerebral Vasoconstriction Syndrome due to Atovaquone
by: Takahiro Makino, et al.
Published: (2017-12-01)

A review on characteristics and analytical methods of atovaquone – a potent antimalarial agent
by: Sanyam Sharma, et al.
Published: (2020-08-01)

Atovaquone for treatment of COVID-19: A prospective randomized, double-blind, placebo-controlled clinical trial
by: Mamta K. Jain, et al.
Published: (2022-09-01)

Atovaquone, chloroquine, primaquine, quinine and tetracycline: antiproliferative effects of relevant antimalarials on Neospora caninum
by: Luiz Miguel Pereira, et al.
Published: (2021-03-01)

A Case of Severe Pneumocystis Pneumonia in an HIV-Negative Patient Successfully Treated with Oral Atovaquone
by: Hirai J, et al.
Published: (2023-03-01)

Formulation and evaluation of atovaquone-loaded macrophage-derived exosomes against Toxoplasma gondii: in vitro and in vivo assessment
by: Fatemeh Goudarzi, et al.
Published: (2024-01-01)

Atovaquone smart lipid system: Design, statistical optimization, and in-vitro evaluation
by: Hardik Rana, et al.
Published: (2023-12-01)

Malarone® induced pancreatitis and alopecia in a dog: a case report
by: Hyeong-Il Choi, et al.
Published: (2019-09-01)

Atovaquone inhibits colorectal cancer metastasis by regulating PDGFRβ/NF-κB signaling pathway
by: Bin Liu, et al.
Published: (2023-11-01)

Data on the combined effect of atovaquone, mefloquine, and 3-bromopyruvic acid against Echinococcus multilocularis protoscoleces
by: Hirokazu Kouguchi, et al.
Published: (2022-12-01)

The effects of serum lipids on the <it>in vitro</it> activity of lumefantrine and atovaquone against <it>Plasmodium falciparum</it>
by: Chotivanich Kesinee, et al.
Published: (2012-05-01)

Atovaquone Suppresses the Growth of Metastatic Triple-Negative Breast Tumors in Lungs and Brain by Inhibiting Integrin/FAK Signaling Axis
by: Nehal Gupta, et al.
Published: (2021-05-01)

Prevention of Tumor Growth and Dissemination by In Situ Vaccination with Mitochondria‐Targeted Atovaquone
by: Mofei Huang, et al.
Published: (2022-04-01)

Atovaquone exerts its anticancer effect by inhibiting Na+/K+-ATPase ion transport in canine cancer cells
by: Yousef Alharbi
Published: (2023-06-01)

Validation of atovaquone plasma levels by liquid chromatography-tandem mass spectrometry for therapeutic drug monitoring in pediatric patients
by: Thomas D. Horvath, et al.
Published: (2022-11-01)

Absence of an interaction between artesunate and atovaquone--proguanil.
by: van Vugt, M, et al.
Published: (1999)

Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate-atovaquone-proguanil.
by: van Vugt, M, et al.
Published: (2002)

Repeated imidocarb treatment failure suggesting emerging resistance of Babesia canis in a new endemic area in north-eastern Germany
by: Christiane Weingart, et al.
Published: (2024-05-01)

The Protozoan Inhibitor Atovaquone Affects Mitochondrial Respiration and Shows In Vitro Efficacy Against Glucocorticoid-Resistant Cells in Childhood B-Cell Acute Lymphoblastic Leukaemia
by: Yordan Sbirkov, et al.
Published: (2021-03-01)

Atovaquone-HSA nano-drugs enhance the efficacy of PD-1 blockade immunotherapy by alleviating hypoxic tumor microenvironment
by: Simeng Wang, et al.
Published: (2021-10-01)

Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells
by: Nehal Gupta, et al.
Published: (2021-05-01)

The mosquito transmission of malaria: the effects of atovaquone-proguanil (Malarone) and chloroquine.
by: Enosse, S, et al.
Published: (2000)

Inhibition of the mosquito transmission of Plasmodium berghei by Malarone (atovaquone-proguanil).
by: Butcher, G, et al.
Published: (2000)

The pharmacokinetics of atovaquone and proguanil in pregnant women with acute falciparum malaria.
by: Mcgready, R, et al.
Published: (2003)